Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

NCT04810962 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

370

Enrollment

INDUSTRY

Sponsor class

Conditions

Ocular Inflammation and Pain After Cataract Surgery

Interventions

DRUG: APP13007, 0.05%
DRUG: Matching Vehicle Placebo for APP13007, 0.05%

Sponsor

Formosa Pharmaceuticals, Inc.